Skip to main content
OpenTrials
Completed

NCT Number: NCT01373606

A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1

This is an open-label, multi-center study, investigating the efficacy and safety of terlipressin in Japanese patients with hepatorenal syndrome type 1.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Investigational site, Kansai, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who were diagnosed with HRS type 1 according to the diagnostic criteria of HRS and whose serum creatinine value (SCr) doubled at 2.5 mg/dL or greater within 2 weeks or whose 24h creatinine clearance (Ccr) decreased by half at less than 20 mL/min.

Patients should meet all the following 5 criteria:

[Modified International Ascites Club's Diagnostic criteria of HRS]

  • Chronic or acute liver disease with advanced hepatic failure and portal hypertension.
  • Low glomerular filtration rate (SCr >1.5 mg/dL or 24h Ccr <40 mL/min)
  • Absence of shock, ongoing bacterial infection, current or recent (within 2 weeks) treatment with nephrotoxic drug
  • No sustained improvement in renal function (decrease in SCr to 1.5 mg/dL or less or increase in 24h Ccr to 40 mL/min or more) following diuretic withdrawal and expansion of plasma volume with 1,500 mL/24h of isotonic saline for 24 to 48h.
  • Protein urea <500 mg/dL, and no ultrasonographic evidence of obstructive uropathy or parenchymal renal disease
  • Age; 20 to 79 years

Exclusion criteria

  • Cr value ≥5 mg/dL
  • Child-Pugh Score ≥14
  • Fulminant hepatitis
  • Septic shock
  • Hepatocellular carcinoma that does not meet the Milan Criteria
  • Acute renal failure caused by contrast medium
  • Chronic renal failure
  • Bradycardia (heart rate <50/min)
  • Hyponatraemia (serum Na <120 mEq/L)
  • Ischemic heart diseases (angina pectoris, myocardial infarction), heart failure or clinically relevant arrhythmia
  • Poor-controlled hypertension
  • Arteriosclerosis obliterans or peripheral vascular disorder
  • Cerebrovascular disorder
  • Respiratory diseases such as chronic obstructive pulmonary disease
  • Pregnant or possibly pregnant women and patients who or whose partner desire -pregnancy during the study period
  • Patients considered by the investigator or sub-investigator as unsuitable to participate in the study

Treatment and study plan

Terlipressin

Drug

Primary outcomes

  1. Change in SCr value from baseline to end of treatment

    Time frame: 16 days

Secondary outcomes

  1. Incidence of adverse events and its severity

    Time frame: Up to 84 days

  2. Laboratory test values

    Time frame: Up to 84 days

  3. Vital signs

    Time frame: 16 days

  4. ECG

    Time frame: Day 1,4,7,10,13,16

  5. The percentage of patients with Hepatorenal syndrome reversal (SCr value <=1.5 mg/dL)

    Time frame: 16 days

  6. The percentage of patients showing 20% or more reduction in SCr value from the baseline

    Time frame: 16 days

  7. 24h Ccr, urine volume, urea nitrogen (BUN), urinary sodium excretions

    Time frame: 16 days

  8. Mean arterial blood pressure, serum Na, serum K, plasma renin activity, aldosterone, norepinephrine, antidiuretic hormone (ADH), atrial natriuresis peptide (ANP)

    Time frame: 16 days

  9. Overall survival

    Time frame: Up to 84 days

  10. Pharmacokinetics - assessment of blood concentration

    Time frame: Blood PK sample collection: pre-dose, 5, 15, 30, 60, 90, 120, 150, 180, 240, and 360 minutes post-dose

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Official study title

An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1

Acronym: HRS

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Jun 15, 2011
Registry last updated
Feb 14, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.